Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 7/20 | 0.36 |
| ▸ | CSF1R | P07333 | 2/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862127 | 0.74 | MEN1 (0.55) | PARP1MAP2K1MEN1KMT2ATDP1 | |
| SCHEMBL1040177 | 0.74 | MEN1 (0.43) | HPGDALDH1A1PARP1MAP2K1MEN1 | |
| SCHEMBL2885084 | 0.73 | MAP2K1 (0.44) | PARP1MAP2K1PTGESMEN1KMT2A | |
| SCHEMBL13636440 | 0.73 | ALDH1A1 (0.50) | HPGDALDH1A1RAB9ASMN1; SMN2PARP1 | |
| SCHEMBL3860786 | 0.72 | MEN1 (0.41) | PARP1MAP2K1PTGESMEN1KMT2A | |
| SCHEMBL1040434 | 0.72 | NR4A2 (0.40) | HPGDALDH1A1RAB9ASMN1; SMN2CSF1R | |
| SCHEMBL2877121 | 0.71 | PTGS2 (0.43) | HPGDALDH1A1RAB9ASMN1; SMN2CSF1R | |
| SCHEMBL17625884 | 0.71 | ALDH1A1 (0.39) | HPGDALDH1A1RAB9ASMN1; SMN2CSF1R | |
| SCHEMBL3864888 | 0.71 | MEN1 (0.40) | PARP1MAP2K1PTGESMEN1KMT2A | |
| SCHEMBL1042057 | 0.69 | MAP2K1 (0.41) | HPGDALDH1A1MAP2K1CNR2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842816-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2010-11-30 | — | — | US | claimed |
| EP-1663210-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2009-04-22 | — | — | EP | claimed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | claimed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | claimed |
| JP-2007504139-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | HPGD 2309/4885ALDH1A1 1591/4885RAB9A 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.